Thu, Aug 21, 2014, 7:21 AM EDT - U.S. Markets open in 2 hrs 9 mins

Recent

% | $
Quotes you view appear here for quick access.

BB&T Corporation Message Board

davehall25 1 post  |  Last Activity: Jul 31, 2014 5:30 PM Member since: Dec 23, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • At the end of the conference call, company officials said that revenue due to Imbruvica sales have outpaced expectations to an extent that previous Q3 and yearly revenue numbers are obsolete and going forward they are not providing quarterly guidance.
    * Imbruvica is the number 2 all time oncology drug by sales in the first four quarters since launch, second only to Avastin.
    *Qtr/Qtr growth of bottles shipped and revenue from Imbruvica from Q114 to Q214 is 94%.
    *Imbruvica market share for CLL/MLL patients. Q413 6%/20% - Q114 26%/35% - Q214 36%/40%
    *A large percentage of increased expense are due to increased marketing of Imbruvica in the US and Europe.
    * Europe sales expected to begin in the Fall of 2014

    All of this data is available on the conference call which is archived at the company's website under investor relations.

BBT
36.79+0.05(+0.14%)Aug 20 4:02 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.